Posted by Michael Wonder on 30 Mar 2021
Incyte announces the European Commission approval of Pemazyre (pemigatinib) as a treatment for adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement
29 March 2021 - Pemazyre is the first targeted therapy approved in the European Union for this indication.
Incyte today announced that the European Commission has approved Pemazyre (pemigatinib) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
